Enoxaparin Dosing Considerations in Renal Impairment

Introduction to Enoxaparin Dosing

For patients with severe renal impairment, the American College of Cardiology recommends reducing enoxaparin to 1 mg/kg subcutaneously once daily for therapeutic anticoagulation, as standard dosing increases major bleeding risk nearly 4-fold without providing additional VTE protection 1, 2

The American Heart Association suggests that for patients with normal renal function, a standard dose of 1 mg/kg subcutaneously every 12 hours is recommended for therapeutic anticoagulation 3
For moderate renal impairment, consider dose reduction to 0.8 mg/kg every 12 hours after the first full dose, as enoxaparin clearance decreases by 31% in moderate renal impairment 1, 2
For severe renal impairment, reduce to 1 mg/kg subcutaneously once daily, as enoxaparin clearance decreases by 44% in severe renal impairment 1, 2, 3

For patients with normal renal function, a standard dose of 40 mg subcutaneously once daily is recommended for prophylactic anticoagulation 4, 5, 6
For severe renal impairment, reduce to 30 mg subcutaneously once daily, as this is the only FDA-approved prophylactic dosing recommendation for severe renal impairment among all low-molecular-weight heparins 2

For elderly patients, the American College of Cardiology recommends 0.75 mg/kg subcutaneously every 12 hours without IV bolus for acute coronary syndrome, regardless of renal function 2
For underweight patients with severe renal impairment, 30 mg subcutaneously once daily is recommended for prophylaxis, as both underweight status and severe renal impairment independently increase bleeding risk 1

Monitor anti-Xa levels in all patients with CrCl <30 mL/min receiving prolonged treatment, and check peak anti-Xa levels 4 hours after administration, only after 3-4 doses have been given 1, 2
Target anti-Xa ranges for therapeutic dosing are 0.5-1.0 IU/mL for twice-daily dosing and >1.0 IU/mL for once-daily dosing 1

Fondaparinux is absolutely contraindicated when CrCl <30 mL/min, and never use fondaparinux in dialysis patients 1, 4, 5, 6
Never switch between enoxaparin and unfractionated heparin mid-treatment, as this significantly increases bleeding risk 1, 2, 3

For severe renal impairment requiring therapeutic anticoagulation, unfractionated heparin is preferred, with dosing of 60 IU/kg IV bolus followed by 12 IU/kg/hour infusion, and adjust to maintain aPTT at 1.5-2.0 times control 1, 2

The American College of Cardiology recommends an alternative once-daily regimen of 1.5 mg/kg subcutaneously once daily, though twice-daily dosing may be more efficacious based on post hoc data 7

Enoxaparin clearance decreases by 31% in moderate renal impairment, and research evidence shows a 4.7-fold increased odds of major bleeding in patients with CrCl 30-50 mL/min receiving standard dosing 8

The National Comprehensive Cancer Network recommends avoiding enoxaparin in patients with active heparin-induced thrombocytopenia; use direct thrombin inhibitors or fondaparinux instead (if renal function permits) 8